For definitions of drug development terms, visit: http://www.pewtrusts.org/en/research-and-analysis/analysis/2014/03/12/from-lab-bench-to-bedside-a-backgrounder-on-drug-development. Note: The following drugs have been removed from the pipeline. They will be included in future updates if development resumes:
September 2017: The antibiotics pipeline was expanded to include global development. With the expanded global methodology, the following antibiotics were added: lascufloxacin, AIC499, and AAI-101. Ramoplanin and TD-1607 were removed during the September 2017 review because they were no longer included in the research and development pipelines on the company’s website. Aztreonam + Avibactam was removed from the pipeline because Avibactam is an approved beta-lactamase inhibitor.
March 2017 review: Ceftaroline + Avibactam was removed because it was no longer included in the research and development pipelines on the company’s website.
September 2016 review: BAL30072 was removed because it was no longer included in the research and development pipelines on the company website.
March 2016 review: Radezolid, Debio 1452, avarofloxacin, and surotomycin were removed. Radezolid was removed because systemic indications for this product were no longer included in the development plans listed on the sponsor website. Debio 1452, avarofloxacin, and surotomycin were no longer included in the research and development pipelines on the company website.
September 2015 review: No changes.
March 2015 review: No changes.
December 2014 review: EDP-788 (Enanta Pharmaceuticals) and TD-1792 (Theravance Biopharma) were
removed. These drugs were either no longer included in the research and development pipelines on the company website, or there was direct communication from the company regarding the status of the drugs. Additionally, GSK-2696266, which had been removed during the September.
September 2014 review: GSK-2696266 and GSK-1322322 (GlaxoSmithKline), ACHN-975 (Achaogen),
and LFF571 (Novartis) were removed during the September 2014 review. These drugs were either no longer included in the research and development pipelines on the company website, or there was direct communication from the company regarding the status of the drugs.
June 2014 review: Ceftobiprole, an antibiotic developed by Basilea Pharmaceutica, had been included in
our analysis; however, the company announced in June 2014 that it is not pursuing further development in
the United States until a partner has been acquired. In April 2016, Basilea announced a partnership with
BARDA for phase 3 development of ceftobiprole in the United States. This product will be included in our
pipeline once development commences.
* Michael Hay et al., “Clinical Development Success Rates for Investigational Drugs,” Nature Biotechnology 32, no. 1 (2014): 40–51, doi:10.1038/nbt.2786. See more at http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development.
- Drugs with the potential to treat C. difficile-associated disease are also included in this resource, even though they do not necessarily work systemically, as the CDC cited C. difficile as an urgent public health threat in a 2013 report (Antibiotic Resistance Threats in the United States, 2013, Sept. 16, 2013, http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf). Specifically excluded are drugs to treat mycobacterial infections, such as tuberculosis and Mycobacterium avium complex, Helicobacter pylori, and biothreat pathogens. Locally acting drugs such as topical, ophthalmic, and inhaled products are also excluded. Biological products, including vaccines and antibodies, are tracked separately in Pew’s nontraditional pipeline (“Nontraditional Products for Bacterial Infections in Clinical Development,” http://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2017/nontraditional-products-for-bacterial-infections-in-clinical-development).
- Based on the most advanced development phase for any indication according to trials registered in a government clinical trial registry (United States, http://www.clinicaltrials.gov, Australian New Zealand Clinical Trials Registry, http://www.anzctr.org.au/, European Union Clinical Trials Register, https://www.clinicaltrialsregister.eu/, Japan Pharmaceutical Information Center, http://www.clinicaltrials.jp/), unless direct communication from the company indicated differently. If no trials were included in a clinical trial registry, then the phase listed on the company website or provided directly by the company is noted by endnote 6. Antibiotics that have been approved will remain listed for one year following approval of the initial indication. The country and regulatory agency that approved the drug will be indicated in parentheses. Antibiotics that are approved in a country outside the U.S. but are still in clinical development for the U.S. market will remain on the pipeline and noted.
- A ‘yes’ in this column indicates that a drug has in vitro data showing both activity against one or more Gram-negative bacteria that are considered ESKAPE pathogens (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, or Enterobacter species) and the potential for clinically significant improved coverage of resistant isolates of these species relative to currently available antibiotics. Excluded are drugs that may have shown in vitro activity but currently have no relevant indications listed in this pipeline. This generally does not apply to phase 1 drugs whose indications are often unknown. Three drugs are listed as ‘possibly’ according to these criteria. It is suspected that SPR741 will meet the criteria for this column, but is listed as ‘possibly’ pending identification of the beta-lactam antibiotic with which it will be combined. Similarly, there are currently no publicly available in vitro data for AIC499 however information found in company press releases suggests that this product will meet the criteria for this column. This column focuses on only one area of unmet medical need. However, stakeholders often highlight resistant Gram-negative ESKAPE pathogens as an area in which innovation is urgently needed and drug discovery and development are particularly challenging. This column is based on information available in the literature, but we welcome any additional information a company may be able to provide. The column definition was revised in March 2015. In previous versions of this chart, the column included all drugs with Gram-negative activity (including drugs active against Neisseria gonorrhoeae or Haemophilus influenzae).
- A ‘yes’ in this column indicates a drug with the potential to address one of the pathogens identified by the CDC as an urgent threat or World Health Organization (WHO) critical threat. The target pathogen is listed in parentheses. CDC urgent threats include C. difficile, carbapenem-resistant Enterobacteriaceae (CRE), and drug-resistant N. gonorrhoeae. WHO antibiotic-resistant critical priority pathogens include carbapenem-resistant A. baumannii (CRAB), carbapenem-resistant P. aeruginosa (CRPA), and carbapenem-resistant/extended spectrum β-lactamase producing Enterobacteriaceae (WHO, “Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics” (2017), http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en). Excluded are drugs that may have shown in vitro activity but currently have no relevant indications listed in this pipeline. This generally does not apply to phase 1 drugs whose indications are often unknown. AIC499 and SPR741are listed as ‘possibly’ in this column, for the same reasons as explicated in Note 3. This column was revised in September 2017 to include WHO’s critical threat pathogens.
- Based on clinical trials currently registered on a government clinical trial registry, and/or reported qualified infectious disease product (QIDP) designations unless otherwise noted. Bolded indications are reported QIDP designations. QIDP designations are given by FDA to antibiotics intended to treat serious or life-threatening infections. QIDPs are eligible to receive benefits under the Generating Antibiotic Incentives Now Act (signed into law as part of the Food and Drug Administration Safety and Innovation Act), including expedited FDA review and extended exclusivity for approved products.
- Information not currently registered on a government clinical trial registry. Information obtained from the company via a corporate website, news release, and/or direct communication.
- This antibiotic has been approved in a country outside the U.S., but remains on the pipeline since it is currently in development for the U.S. market. Nemonoxacin has been approved for community-acquired bacterial pneumonia in Taiwan, Province of China and China. Taksta (fusidic acid) has been approved for acute bacterial skin and soft tissue infections in outside markets. Ceftobiprole has been approved for community-acquired pneumonia and hospital-acquired bacterial pneumonia in outside markets. SPR994 has been approved for pneumonia, otitis media, and sinusitis in Japan.
- This drug has been granted an orphan designation from the FDA. Taksta received designation for the indication of prosthetic joint infections and Iclaprim for cystic fibrosis lung infections.
- Products added after expanded methodology in September 2017 pipeline update to include global antibiotic development (see methodology section for further details on determining product inclusion). Currently, there is no public information available indicating that these antibiotics are in development for the U.S. market.
- In February 2015, FDA approved an otic suspension formulation of finafloxacin to treat acute otitis externa. Because a systemic formulation of finafloxacin has not received approval in any country, this drug remains listed in our pipeline. Finafloxacin has shown the potential for improved activity under certain conditions, namely acidic environments. Additionally, a company press release noted that phase 2 complicated urinary tract infection study results have shown improved clinical outcomes in patients treated with finafloxacin compared with patients treated with the current standard of care.
- A novel drug class is defined as a core chemical structure (scaffold) that has not previously been used systemically as an antibacterial in humans.
- A target is defined as novel if the drug acts on a bacterial structure that has not previously been targeted by a systemic antibacterial in humans.
- Vaborbactam is a cyclic boronate β-lactamase inhibitor and is combined with a previously approved carbapenem. β-lactamase inhibitors have been paired with β-lactams in the past, but this β-lactamase inhibitor has a novel chemical structure.
- SPR741 is an antibiotic potentiator that makes the outer membrane of Gram-negative bacteria more permeable, increasing the entry and, therefore, the efficacy of antibiotics. The antibiotic that SPR741 will be paired with has not yet been announced.
- Delpazolid (LCB01-0371) is also in development for tuberculosis but remains on the pipeline since it is also being developed for bacterial infections.
- This is the prodrug form of the antibiotic, which has the same mechanism of action and core chemical structure, and is being developed for the distinct benefit of being able to be administered in other ways, e.g., oral or intravenously.
- Citeline, “Pharmaprojects,” (2012), http://www.citeline.com/products/pharmaprojects.
- U.S. National Institutes of Health, “Search for Studies,” http://www.clinicaltrials.gov.
- Helen W. Boucher et al., “10 x ’20 Progress—Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America,” Clinical Infectious Diseases 56 (2013): 1685–94, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707426.
- Michael J. Pucci and Karen Bush, “Investigational Antimicrobial Agents of 2013,” Clinical Microbiology Reviews 26 (2013): 792–821, http://cmr.as.org/content/26/4/792.
- Centers for Disease Control and Prevention, “Antibiotic Resistance Threats in the United States”, 2013 (2013), http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
- World Health Organization, “Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics”, 2017 (Aug. 28, 2017), http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/.
- World Health Organization, Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline, Including Mycobacterium tuberculosis, 2017, (Sept. 21, 2017), http://www.who.int/medicines/areas/rational_use/antibacterial_agents_clinical_development/en/.